The North America point of care diagnostics market size is expected to reach USD 28.46 billion by 2030, expanding at a CAGR of 6.2% over the forecast period. The growth can be attributed to the rise in the geriatric population and the ability of point-of-care (POC) diagnostic tests to deliver immediate results. Furthermore, a rise in funding from the government & private institutions is a key factor driving the industry’s growth. An increase in the adoption of mobile diagnostic devices in the region is also one of the key factors driving demand for POC testing.
An increase in funding from multiple sources, including the U.S. department of defense (DOD), NIH, and private foundations such as the Bill & Melinda Gates Foundation, is expected to drive the market’s growth. For instance, Grand Challenges Canada and the Bill & Melinda Gates Foundation have launched a joint initiative for POC diagnostics. These organizations are involved in the development and integration of different diagnostic components into interoperable POC platforms with “plug-and-play” characteristic features and the capability of running diverse tests from various developers. Research is conducted to incorporate each test on a common platform with a single interface, enabling analysis of different sample specimens using various approaches for analysis.
Such institutions are involved in funding various projects for the development of POC diagnostics to different organizations including California Institute of Technology, Dartmouth College, and Seventh Sense Biosystems. Moreover, NIH, through the Point-of-Care Technologies Research Network, has been funding the development of these technologies for screening infectious diseases & cancer as well as for primary care. In August 2022, Nanopath, Inc. received funding of USD 10 million from Medtech Convergence Fund and Norwest Venture Partners with participation from Green D Ventures and Gingerbread Capital. The funding would help develop POC diagnostics for women’s health.
Key players operating in the market are focusing on collaboration for the development of new products. For instance, in December 2021, QIAGEN and Denovo Biopharma LLC announced a partnership to establish a blood-based companion diagnostic test. Moreover, the companies are also emphasizing on launching of innovative technologies to increase the efficiency of diagnostic testing. For instance, in 2021, F. Hoffmann-La Roche Ltd launched a new blood glucose meter Accu-Chek Instant system, which helped the company expand its personalized diabetes management business.
An increase in funding from multiple sources, including the U.S. department of defense (DOD), NIH, and private foundations such as the Bill & Melinda Gates Foundation, is expected to drive the market’s growth. For instance, Grand Challenges Canada and the Bill & Melinda Gates Foundation have launched a joint initiative for POC diagnostics. These organizations are involved in the development and integration of different diagnostic components into interoperable POC platforms with “plug-and-play” characteristic features and the capability of running diverse tests from various developers. Research is conducted to incorporate each test on a common platform with a single interface, enabling analysis of different sample specimens using various approaches for analysis.
Such institutions are involved in funding various projects for the development of POC diagnostics to different organizations including California Institute of Technology, Dartmouth College, and Seventh Sense Biosystems. Moreover, NIH, through the Point-of-Care Technologies Research Network, has been funding the development of these technologies for screening infectious diseases & cancer as well as for primary care. In August 2022, Nanopath, Inc. received funding of USD 10 million from Medtech Convergence Fund and Norwest Venture Partners with participation from Green D Ventures and Gingerbread Capital. The funding would help develop POC diagnostics for women’s health.
Key players operating in the market are focusing on collaboration for the development of new products. For instance, in December 2021, QIAGEN and Denovo Biopharma LLC announced a partnership to establish a blood-based companion diagnostic test. Moreover, the companies are also emphasizing on launching of innovative technologies to increase the efficiency of diagnostic testing. For instance, in 2021, F. Hoffmann-La Roche Ltd launched a new blood glucose meter Accu-Chek Instant system, which helped the company expand its personalized diabetes management business.
North America Point Of Care Diagnostics Market Report Highlights
- The growth of the overall market is attributed to the increasing emphasis on point-of-care testing due to superior efficiency and minimal diagnostic turnaround time
- Increase in funding from multiple sources, including the U.S. department of defense (DOD), NIH, and private foundations such as the Bill & Melinda Gates Foundation is expected to increase the launch of new PoC diagnostic technologies in North America
- The infectious diseases product segment held the largest market share owing to the substantial adoption of COVID-19 diagnostic kits and the introduction of new PoC kits for respiratory conditions
- The clinic end-use segment dominated the market with the highest revenue share in 2022. This is attributed to the population’s preference for clinics due to convenience
- The LDT type segment held a marginal share of the North America PoC diagnostics industry in 2022, owing to stringent authority regulations
- The U.S. dominated the market in 2022, due to the presence of key players and the rising support from the government for the development of advanced technologies
Table of Contents
Chapter 1 Methodology And Scope1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Research Methodology
1.4 Definitions
1.5 Information Procurement
1.5.1 Purchased Database
1.5.2 Internal Database
1.5.3 Secondary Sources
1.5.4 Primary Research
1.5.5 Details Of Primary Research
1.6 Information Or Data Analysis
1.6.1 Market Categorization
1.6.2 Point - Of - Care Testing
1.6.2.1 Poc - End - Use Penetration Mapping
1.6.3 Data Analysis Models
1.7 Market Formulation & Validation
1.8 Model Details
1.8.1 Commodity Flow Analysis
1.8.1.1 Approach 1: Commodity Flow Approach
1.8.1.2 Approach 2: Country - Wise Market Estimation Using The Bottom - Up Approach
1.9 North America Market: Cagr Calculation
1.10 List Of Secondary Sources
1.11 List Of Primary Sources
1.12 Objectives
1.12.1 Objective 1:
1.12.2 Objective 2:
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Market Summary
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Market Variables, Trends, And Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.1.3 Molecular Technology Intervention
3.1.3.1 Key Factors Considered For Analyzing Molecular Technology Interventions Across Point-Of-care (Poc) Testing
3.2 Penetration And Growth Prospect Mapping For Poc Products, 2022
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Introduction Of Clia - Waived Tests
3.3.1.2 Rise In Funding From Government And Private Institutions
3.3.1.3 Growing Geriatric Population
3.3.1.4 Growing Prevalence Of Targeted Diseases
3.3.1.5 Growing Demand For Home Healthcare And Introduction Of Advanced Technology - Enabled Products
3.3.2 Market Restraint Analysis
3.3.2.1 Presence Of Ambiguous Regulatory Framework
3.3.3 Market Challenge Analysis
3.3.3.1 Poc Devices Pose Challenges In Maintaining Quality Standards
3.3.4 Market Opportunity Analysis
3.3.4.1 Networking & Remote Access Integration Of Poc Diagnostics Products
3.3.4.1.1 Smartphone Orientation
3.3.4.1.2 Embedded Vision - Based Solutions
3.3.4.1.3 Digital Technologies
3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis - Porter’s
3.6 Market Entry Strategies
3.7 Price - Cost - Margin Analysis For Poc Testing
3.8 User Perspective Analysis
3.8.1 Consumer Behavior Analysis
3.9 Technology Overview
3.10 Poc Diagnostics: Market Influencers
3.10.1 High Sensitivity
3.10.2 Shift To Molecular Diagnostics
3.10.3 Glucose Testing
3.10.4 Hba1c Testing
3.10.5 Coagulation Testing
3.10.6 Fertility Testing
3.10.7 Infectious Disease
3.10.8 Cardiac Markers
3.10.9 Thyroid - Stimulating Hormone
3.10.10 Hematology
3.10.11 Primary Care Systems
3.10.12 Decentralized Clinical Chemistry
3.10.13 Feces
3.10.14 Lipid Testing
3.10.15 Cancer Marker
3.10.16 Blood Gas/Electrolytes
3.10.17 Ambulatory Chemistry
3.10.18 Drug Of Abuse (Doa) Testing
3.10.19 Urinalysis
3.11 Covid - 19 Impact Analysis
3.12 Overview
3.12.1 Covid - 19 Point - Of - Care Diagnostics: Technology Overview
3.12.2 Covid - 19 Point - Of - Care Diagnostics: Regulatory Overview
3.12.3 Covid - 19 Point - Of - Care Diagnostics: Competitive Landscape
Chapter 4 Product Business Analysis
4.1 North America Point - Of - Care (Poc) Diagnostics Market: Product Movement Analysis
4.2 Glucose Testing
4.2.1 Glucose Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.2.2 Glucose Testing Market, By End - Use
4.2.2.1 Glucose Testing Market, By Hospital
4.2.2.2 Glucose Testing Market, By Laboratories
4.2.2.3 Glucose Testing Market, By Home Care
4.2.2.4 Glucose Testing Market, By Clinic
4.2.2.5 Glucose Testing Market, By Physician Office
4.2.2.6 Glucose Testing Market, By Pharmacy & Retail Clinics
4.2.2.7 Glucose Testing Market, By Non - Practice Clinics
4.2.2.8 Glucose Testing Market, By Urgent Care Clinics
4.2.2.9 Glucose Testing Market, By Others
4.2.2.10 Glucose Testing Market, By Rural Health Clinic
4.2.2.11 Glucose Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.2.3 Glucose Testing Market, By Disease
4.2.3.1 Diabetes
4.2.3.2 Glucose Testing Market, By Diabetes
4.2.3.3 Others
4.2.3.4 Glucose Testing Market, By Others
4.3 Hba1c Testing
4.3.1 Hba1c Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.3.2 Hba1c Testing Market, By End - Use
4.3.2.1 Hba1c Testing Market, By Hospital
4.3.2.2 Hba1c Testing Market, By Laboratories
4.3.2.3 Hba1c Testing Market, By Home Care
4.3.2.4 Hba1c Testing Market, By Clinic
4.3.2.5 Hba1c Testing Market, By Physician Office
4.3.2.6 Hba1c Testing Market, By Pharmacy & Retail Clinics
4.3.2.7 Hba1c Testing Market, By Non - Practice Clinics
4.3.2.8 Hba1c Testing Market, By Urgent Care Clinics
4.3.2.9 Hba1c Testing Market, By Others
4.3.2.10 Hba1c Testing Market, By Rural Health Clinic
4.3.2.11 Hba1c Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.3.3 Hba1c Testing Market, By Disease
4.3.3.1 Diabetes
4.3.3.2 Hba1c Testing Market, By Diabetes
4.3.3.3 Others
4.3.3.4 Hba1c Testing Market, By Others
4.4 Coagulation Testing
4.4.1 Coagulation Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.4.2 Coagulation Testing Market, By End - Use
4.4.2.1 Coagulation Testing Market, By Hospital
4.4.2.2 Coagulation Testing Market, By Laboratories
4.4.2.3 Coagulation Testing Market, By Home Care
4.4.2.4 Coagulation Testing Market, By Clinic
4.4.2.5 Coagulation Testing Market, By Physician Office
4.4.2.6 Coagulation Testing Market, By Pharmacy & Retail Clinics
4.4.2.7 Coagulation Testing Market, By Non - Practice Clinics
4.4.2.8 Coagulation Testing Market, By Urgent Care Clinics
4.4.2.9 Coagulation Testing Market, By Others
4.4.2.10 Coagulation Testing Market, By Rural Health Clinic
4.4.2.11 Coagulation Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.4.3 Coagulation Testing Market, By Disease
4.4.3.1 Thrombosis
4.4.3.2 Coagulation Testing Market, By Thrombosis
4.4.3.3 Hemophilia
4.4.3.4 Coagulation Testing Market, By Hemophilia
4.4.3.5 Others
4.4.3.6 Coagulation Testing Market, By Others
4.5 Fertility/Pregnancy
4.5.1 Fertility/Pregnancy Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.5.2 Fertility Testing Market, By End - Use
4.5.2.1 Fertility Testing Market, By Hospital
4.5.2.2 Fertility Testing Market, By Laboratories
4.5.2.3 Fertility Testing Market, By Home Care
4.5.2.4 Fertility Testing Market, By Clinic
4.5.2.5 Fertility Testing Market, By Physician Office
4.5.2.6 Fertility Testing Market, By Pharmacy & Retail Clinics
4.5.2.7 Fertility Testing Market, By Non - Practice Clinics
4.5.2.8 Fertility Testing Market, By Urgent Care Clinics
4.5.2.9 Fertility Testing Market, By Others
4.5.2.10 Fertility Testing Market, By Rural Health Clinic
4.5.2.11 Fertility Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.5.3 Fertility Testing Market, By Type
4.5.3.1 Lh - Ovulation Elite Tes
4.5.3.2 Fertility Testing Market, By Lh - Ovulation Elite Test
4.5.3.3 Hcg - Pregnancy Tests
4.5.3.4 Fertility Testing Market, By Hcg - Pregnancy Tests
4.5.3.5 Fertility Tests
4.5.3.6 Fertility Testing Market, By Fertility Tests
4.5.3.7 Others
4.5.3.8 Fertility Testing Market, By Others
4.6 Infectious Disease Testing
4.6.1 Infectious Disease Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.6.2 Infectious Disease Testing Market, By End - Use
4.6.2.1 Infectious Disease Testing Market, By Hospital
4.6.2.2 Infectious Disease Testing Market, By Laboratories
4.6.2.3 Infectious Disease Testing Market, By Home Care
4.6.2.4 Infectious Disease Testing Market, By Clinic
4.6.2.5 Infectious Disease Testing Market, By Physician Office
4.6.2.6 Infectious Disease Testing Market, By Pharmacy & Retail Clinics
4.6.2.7 Infectious Disease Testing Market, By Non - Practice Clinics
4.6.2.8 Infectious Disease Testing Market, By Urgent Care Clinics
4.6.2.9 Infectious Disease Testing Market, By Others
4.6.2.10 Infectious Disease Testing Market, By Rural Health Clinic
4.6.2.11 Infectious Disease Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.6.3 Infectious Disease Testing Market, By Disease
4.6.3.1 Hiv Poc
4.6.3.2 Infectious Disease Testing Market, By Hiv Poc
4.6.3.3 Clostridium Difficile Poc
4.6.3.4 Infectious Disease Testing Market, By Clostridium Difficile Poc
4.6.3.5 Hbv Poc
4.6.3.6 Infectious Disease Testing Market, By Hbv Poc
4.6.3.7 Pneumonia Or Streptococcus - Associated Infections
4.6.3.8 Infectious Disease Testing Market, By Pneumonia Or Streptococcus Associated Infections
4.6.3.9 Respiratory Syncytial Virus Poc
4.6.3.10 Infectious Disease Testing Market, By Respiratory Syncytial Virus (Rsv) Poc
4.6.3.11 Hpv Poc
4.6.3.12 Infectious Disease Testing Market, By Hpv Poc
4.6.3.13 Influenza/Flu Poc
4.6.3.14 Infectious Disease Testing Market, By Influenza/Flu Poc
4.6.3.15 Hcv Poc
4.6.3.16 Infectious Disease Testing Market, By Hcv Poc
4.6.3.17 Mrsa Poc
4.6.3.18 Infectious Disease Testing Market, By Mrsa Poc
4.6.3.19 Tb And Drug - Resistant Tb Poc
4.6.3.20 Infectious Disease Testing Market, By Tb And Drug - Resistant Tb Poc
4.6.3.21 Hsv Poc
4.6.3.22 Infectious Disease Testing Market, By Hsv Poc
4.6.3.23 Covid - 19
4.6.3.24 Infectious Disease Testing Market, By Covid - 19
4.6.3.25 Other Infectious Diseases
4.6.3.26 Infectious Disease Testing Market, By Other Infectious Diseases
4.7 Cardiac Markers
4.7.1 Cardiac Markers Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.7.2 Cardiac Markers Market, By End - Use
4.7.2.1 Cardiac Markers Market, By Hospital
4.7.2.2 Cardiac Markers Market, By Laboratories
4.7.2.3 Cardiac Markers Market, By Home Care
4.7.2.4 Cardiac Markers Market, By Clinic
4.7.2.5 Cardiac Markers Market, By Physician Office
4.7.2.6 Cardiac Markers Market, By Pharmacy & Retail Clinics
4.7.2.7 Cardiac Markers Market, By Non - Practice Clinics
4.7.2.8 Cardiac Markers Market, By Urgent Care Clinics
4.7.2.9 Cardiac Markers Market, By Others
4.7.2.10 Cardiac Markers Market, By Rural Health Clinic
4.7.2.11 Cardiac Markers Market, By Federally Qualified Health Clinic (Fqhc)
4.7.3 Cardiac Markers Market, By Disease
4.7.3.1 Acute Coronary Syndrome
4.7.3.2 Cardiac Markers Market, By Acute Coronary Syndrome
4.7.3.3 Myocardial Infarction
4.7.3.4 Cardiac Markers Market, By Myocardial Infarction
4.7.3.5 Congestive Heart Failure
4.7.3.6 Cardiac Markers Market, By Congestive Heart Failure
4.7.3.7 Others
4.7.3.8 Cardiac Markers Market, By Others
4.7.4 Cardiac Markers Market, By Marker
4.8 Thyroid Stimulating Hormone
4.8.1 Thyroid Stimulating Hormone Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.8.2 Thyroid Stimulating Hormone Market, By End - Use
4.8.2.1 Thyroid Stimulating Hormone Market, By Hospital
4.8.2.2 Thyroid Stimulating Hormone Market, By Laboratories
4.8.2.3 Thyroid Stimulating Hormone Market, By Home Care
4.8.2.4 Thyroid Stimulating Hormone Market, By Clinic
4.8.2.5 Thyroid Stimulating Hormone Market, By Physician Office
4.8.2.6 Thyroid Stimulating Hormone Market, By Pharmacy & Retail Clinics
4.8.2.7 Thyroid Stimulating Hormone Market, By Non - Practice Clinics
4.8.2.8 Thyroid Stimulating Hormone Market, By Urgent Care Clinics
4.8.2.9 Thyroid Stimulating Hormone Market, By Others
4.8.2.10 Thyroid Stimulating Hormone Market, By Rural Health Clinic
4.8.2.11 Thyroid Stimulating Hormone Market, By Federally Qualified Health Clinic (Fqhc)
4.8.3 Thyroid Stimulating Hormone Market, By Disease
4.8.3.1 Hyperthyroidism
4.8.3.2 Thyroid Stimulating Hormone Market, By Hyperthyroidism
4.8.3.3 Hypothyroidism
4.8.3.4 Thyroid Stimulating Hormone Market, By Hypothyroidism
4.9 Hematology
4.9.1 Hematology Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.9.2 Hematology Market, By End - Use
4.9.2.1 Hematology Market, By Hospital
4.9.2.2 Hematology Market, By Laboratories
4.9.2.3 Hematology Market, By Home Care
4.9.2.4 Hematology Market, By Clinic
4.9.2.5 Hematology Market, By Physician Office
4.9.2.6 Hematology Market, By Pharmacy & Retail Clinics
4.9.2.7 Hematology Market, By Non - Practice Clinics
4.9.2.8 Hematology Market, By Urgent Care Clinics
4.9.2.9 Hematology Market, By Others
4.9.2.10 Hematology Market, By Rural Health Clinic
4.9.2.11 Hematology Market, By Federally Qualified Health Clinic (Fqhc)
4.9.3 Hematology Market, By Disease
4.9.3.1 Anemia
4.9.3.2 Hematology Market, By Anemia
4.9.3.3 Leukemia
4.9.3.4 Hematology Market, By Leukemia
4.9.3.5 Others
4.9.3.6 Hematology Market, By Others
4.10 Primary Care Systems
4.10.1 Primary Care Systems Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.10.2 Primary Care Systems Market, By End - Use
4.10.2.1 Primary Care Systems Market, By Hospital
4.10.2.2 Primary Care Systems Market, By Laboratories
4.10.2.3 Primary Care Systems Market, By Home Care
4.10.2.4 Primary Care Systems Market, By Clinic
4.10.2.5 Primary Care Systems Market, By Physician Office
4.10.2.6 Primary Care Systems Market, By Pharmacy & Retail Clinics
4.10.2.7 Primary Care Systems Market, By Non - Practice Clinics
4.10.2.8 Primary Care Systems Market, By Urgent Care Clinics
4.10.2.9 Primary Care Systems Market, By Others
4.10.2.10 Primary Care Systems Market, By Rural Health Clinic
4.10.2.11 Primary Care Systems Market, By Federally Qualified Health Clinic (Fqhc)
4.11 Decentralized Clinical Chemistry
4.11.1 Decentralized Clinical Chemistry Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.11.2 Decentralized Clinical Chemistry Market, By End - Use
4.11.2.1 Decentralized Clinical Chemistry Market, By Hospital
4.11.2.2 Decentralized Clinical Chemistry Market, By Laboratories
4.11.2.3 Decentralized Clinical Chemistry Market, By Home Care
4.11.2.4 Decentralized Clinical Chemistry Market, By Clinic
4.11.2.5 Decentralized Clinical Chemistry Market, By Physician Office
4.11.2.6 Decentralized Clinical Chemistry Market, By Pharmacy & Retail Clinics
4.11.2.7 Decentralized Clinical Chemistry Market, By Non - Practice Clinics
4.11.2.8 Decentralized Clinical Chemistry Market, By Urgent Care Clinics
4.11.2.9 Decentralized Clinical Chemistry Market, By Others
4.11.2.10 Decentralized Clinical Chemistry Market, By Rural Health Clinic
4.11.2.11 Decentralized Clinical Chemistry Market, By Federally Qualified Health Clinic (Fqhc)
4.12 Feces
4.12.1 Feces Point - Of - Care (Poc) Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.12.2 Feces Market, By End - Use
4.12.2.1 Feces Market, By Hospital
4.12.2.2 Feces Market, By Laboratories
4.12.2.3 Feces Market, By Home Care
4.12.2.4 Feces Market, By Clinic
4.12.2.5 Feces Market, By Physician Office
4.12.2.6 Feces Market, By Pharmacy & Retail Clinics
4.12.2.7 Feces Market, By Non - Practice Clinics
4.12.2.8 Feces Market, By Urgent Care Clinics
4.12.2.9 Feces Market, By Others
4.12.2.10 Feces Market, By Rural Health Clinic
4.12.2.11 Feces Market, By Federally Qualified Health Clinic (Fqhc)
4.12.3 Feces Market, By Disease
4.12.3.1 Colorectal Cancer
4.12.3.2 Feces Market, By Colorectal Cancer
4.12.3.3 Gi Disorders
4.12.3.4 Feces Market, By Gi Disorders
4.12.3.5 Others
4.12.3.6 Feces Market, By Others
List of Tables
Table 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 North America POC Diagnostics Market, By Product, 2018 - 2030 (USD Million)
TABLE 4 North America POC Diagnostics Market, By End-use, 2018 - 2030 (USD Million)
TABLE 5 North America POC Diagnostics Market, By Type, 2018 - 2030 (USD Million)
TABLE 6 U.S.POC Diagnostics Market, By Product, 2018 - 2030 (USD Million)
TABLE 7 U.S.POC Diagnostics Market, By End-use, 2018 - 2030 (USD Million)
TABLE 8 U.S.POC Diagnostics Market, By Type, 2018 - 2030 (USD Million)
TABLE 9 Canada POC Diagnostics Market, By Product, 2018 - 2030 (USD Million)
TABLE 10 Canada POC Diagnostics Market, By End-use, 2018 - 2030 (USD Million)
TABLE 11 Canada POC Diagnostics Market, By Type, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
FIG. 2 Data triangulation techniques
FIG. 3 Primary research pattern
FIG. 4 Market revenue model
FIG. 5 POC end - use penetration mapping
FIG. 6 Market research approaches
FIG. 7 Value chain - based sizing & forecasting
FIG. 8 QFD modeling for market share assessment
FIG. 9 Market formulation & validation
FIG. 10 Parent market outlook
FIG. 11 Related/ancillary market outlook
FIG. 12 Penetration and growth prospect mapping
FIG. 13 North America point-of-care diagnostics market: Driver relevance analysis (Current & future impact)
FIG. 14 Shift in POC molecular diagnostic trends
FIG. 15 Projected number of persons aged 65 and older, 2000 - 2060 (numbers in millions)
FIG. 16 People with diabetes in the U.S., 2000 - 2045 (numbers in thousands)
FIG. 17 North America point-of-care diagnostics market: Restraint relevance analysis (Current & future impact)
FIG. 18 North America point-of-care diagnostics market: Challenge relevance analysis (Current & future impact)
FIG. 19 North America point-of-care diagnostics market: Opportunity relevance analysis (Current & future impact)
FIG. 20 Accountable factors to ensure adequate accessibility of POC diagnostic solutions
FIG. 21 North America point-of-care diagnostics market - SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 22 Porter’s Five Forces Analysis
FIG. 23 Factors impacting market entry strategies
FIG. 24 Key market entry methods
FIG. 25 Consumption trends for POCT
FIG. 26 COVID - 19 point-of-care diagnostics market: Trend analysis
FIG. 27 COVID - 19 point-of-care diagnostics: Technology landscape
FIG. 28 North America point-of-care (POC) diagnostics market: Product outlook and key takeaways
FIG. 29 North America point-of-care diagnostics market: Product movement analysis
FIG. 30 Glucose testing diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 31 Glucose testing market, by hospital
FIG. 32 Glucose testing market, by laboratories
FIG. 33 Glucose testing market, by home care
FIG. 34 Glucose testing market, by clinic
FIG. 35 Glucose testing market, by physician office
FIG. 36 Glucose testing market, by pharmacy & retail clinics
FIG. 37 Glucose testing market, by non - practice clinics
FIG. 38 Glucose testing market, by urgent care clinics
FIG. 39 Glucose testing market, by others
FIG. 40 Glucose testing market, by rural health clinic
FIG. 41 Glucose testing market, by federally qualified health clinic
FIG. 42 Glucose testing market, by diabetes
FIG. 43 Glucose testing market, by others
FIG. 44 HbA1c testing market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 45 HbA1c testing market, by hospital
FIG. 46 HbA1c testing market, by laboratories
FIG. 47 HbA1c testing market, by home care
FIG. 48 HbA1C testing market, by clinic
FIG. 49 HbA1C testing market, by physician office
FIG. 50 HbA1C testing market, by pharmacy & retail clinics
FIG. 51 HbA1C testing market, by non - practice clinics
FIG. 52 HbA1C testing market, by urgent care clinics
FIG. 53 HbA1C testing market, by others
FIG. 54 HbA1C testing market, by rural health clinic
FIG. 55 HbA1C testing market, by federally qualified health clinic
FIG. 56 HbA1C testing market, by diabetes
FIG. 57 HbA1C testing market, by others
FIG. 58 Coagulation testing market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 59 Coagulation testing market, by hospital
FIG. 60 Coagulation testing market, by laboratories
FIG. 61 Coagulation testing market, by home care
FIG. 62 Coagulation testing market, by clinic
FIG. 63 Coagulation testing market, by physician office
FIG. 64 Coagulation testing market, by pharmacy & retail clinics
FIG. 65 Coagulation testing market, by non - practice clinics
FIG. 66 Coagulation testing market, by urgent care clinics
FIG. 67 Coagulation testing market, by others
FIG. 68 Coagulation testing market, by rural health clinic
FIG. 69 Coagulation testing market, by federally qualified health clinic
FIG. 70 Coagulation testing market, by thrombosis
FIG. 71 Coagulation testing market, by hemophilia
FIG. 72 Coagulation testing market, by others
FIG. 73 Fertility/pregnancy testing market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 74 Fertility testing market, by hospital
FIG. 75 Fertility testing market, by laboratories
FIG. 76 Fertility testing market, by home care
FIG. 77 Fertility testing market, by clinic
FIG. 78 Fertility testing market, by physician office
FIG. 79 Fertility testing market, by pharmacy & retail clinics
FIG. 80 Fertility testing market, by non - practice clinics
FIG. 81 Fertility testing market, by urgent care clinics
FIG. 82 Fertility testing market, by others
FIG. 83 Fertility testing market, by rural health clinic
FIG. 84 Fertility testing market, by federally qualified health clinic
FIG. 85 Fertility testing market, by LH - ovulation elite test
FIG. 86 Fertility testing market, by HCG - pregnancy tests
FIG. 87 Fertility testing market, by fertility tests
FIG. 88 Fertility testing market, by others
FIG. 89 Infectious disease testing market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 90 Infectious disease testing market, by hospital
FIG. 91 Infectious disease testing market, by laboratories
FIG. 92 Infectious disease testing market, by home care
FIG. 93 Infectious disease testing market, by clinic
FIG. 94 Infectious disease testing market, by physician office
FIG. 95 Infectious disease testing market, by pharmacy & retail clinics
FIG. 96 Infectious disease testing market, by non - practice clinics
FIG. 97 Infectious disease testing market, by urgent care clinics
FIG. 98 Infectious disease testing market, by others
FIG. 99 Infectious disease testing market, by rural health clinic
FIG. 100 Infectious disease testing market, by federally qualified health clinic
FIG. 101 Infectious disease testing market, by HIV POC
FIG. 102 Infectious disease testing market, by Clostridium difficile POC, 2018 - 2030 (USD Million)
FIG. 103 Infectious disease testing market, by HBV POC
FIG. 104 Infectious disease testing market, by Pneumonia or Streptococcus Associated Infections
FIG. 105 Infectious disease testing market, by respiratory syncytial virus (RSV) POC
FIG. 106 Infectious disease testing market, by HPV POC
FIG. 107 Infectious disease testing market, by influenza/flu POC
FIG. 108 Infectious disease testing market, by HCV POC
FIG. 109 Infectious disease testing market, by MRSA POC
FIG. 110 Infectious disease testing market, by TB and drug - resistant TB POC
FIG. 111 Infectious disease testing market, by HSV POC
FIG. 112 Infectious disease testing market, by COVID - 19
FIG. 113 Infectious disease testing market, by other infectious diseases
FIG. 114 Cardiac markers market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 115 Cardiac markers market, by hospital
FIG. 116 Cardiac markers market, by laboratories
FIG. 117 Cardiac markers market, by home care
FIG. 118 Cardiac markers market, by clinic
FIG. 119 Cardiac markers market, by physician office
FIG. 120 Cardiac markers market, by pharmacy & retail clinics
FIG. 121 Cardiac markers market, by non - practice clinics
FIG. 122 Cardiac markers market, by urgent care clinics
FIG. 123 Cardiac markers market, by others
FIG. 124 Cardiac markers market, by rural health clinic
FIG. 125 Cardiac markers market, by federally qualified health clinic
FIG. 126 Cardiac markers market, by acute coronary syndrome
FIG. 127 Cardiac markers market, by myocardial infarction
FIG. 128 Cardiac markers market, by congestive heart failure
FIG. 129 Cardiac markers market, by others
FIG. 130 Cardiac markers market, by marker
FIG. 131 Cardiac markers
FIG. 132 Thyroid stimulating hormone market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 133 Thyroid stimulating hormone market, by hospital
FIG. 134 Thyroid stimulating hormone market, by laboratories
FIG. 135 Thyroid stimulating hormone market, by home care
FIG. 136 Thyroid stimulating hormone market, by clinic
FIG. 137 Thyroid stimulating hormone market, by physician office
FIG. 138 Thyroid stimulating hormone market, by pharmacy & retail clinics
FIG. 139 Thyroid stimulating hormone market, by non - practice clinics
FIG. 140 Thyroid stimulating hormone market, by urgent care clinics
FIG. 141 Thyroid stimulating hormone market, by others
FIG. 142 Thyroid stimulating hormone market, by rural health clinic
FIG. 143 Thyroid stimulating hormone market, by federally qualified health clinic
FIG. 144 Thyroid stimulating hormone market, by hyperthyroidism
FIG. 145 Thyroid stimulating hormone market, by hypothyroidism
FIG. 146 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 147 Hematology market, by hospital
FIG. 148 Hematology market, by laboratories
FIG. 149 Hematology market, by home care
FIG. 150 Hematology market, by clinic
FIG. 151 Hematology market, by physician office
FIG. 152 Hematology market, by pharmacy & retail clinics
FIG. 153 Hematology market, by non - practice clinics
FIG. 154 Hematology market, by urgent care clinics
FIG. 155 Hematology market, by others
FIG. 156 Hematology market, by rural health clinic
FIG. 157 Hematology market, by federally qualified health clinic
FIG. 158 Hematology market, by anemia
FIG. 159 Hematology market, by leukemia
FIG. 160 Hematology market, by others
FIG. 161 Primary care systems market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 162 Primary care systems market, by hospital
FIG. 163 Primary care systems market, by laboratories
FIG. 164 Primary care systems market, by home care
FIG. 165 Primary care systems market, by clinic
FIG. 166 Primary care systems market, by physician office
FIG. 167 Primary care systems market, by pharmacy & retail clinics
FIG. 168 Primary care systems market, by non - practice clinics
FIG. 169 Primary care systems market, by urgent care clinics
FIG. 170 Primary care systems market, by others
FIG. 171 Primary care systems market, by rural health clinic
FIG. 172 Primary care systems market, by federally qualified health clinic
FIG. 173 Decentralized clinical chemistry market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 174 Decentralized clinical chemistry market, by hospital
FIG. 175 Decentralized clinical chemistry market, by laboratories
FIG. 176 Decentralized clinical chemistry market, by home care
FIG. 177 Decentralized clinical chemistry market, by clinic
FIG. 178 Decentralized clinical chemistry market, by physician office
FIG. 179 Decentralized clinical chemistry market, by pharmacy & retail clinics
FIG. 180 Decentralized clinical chemistry market, by non - practice clinics
FIG. 181 Decentralized clinical chemistry market, by urgent care clinics
FIG. 182 Decentralized clinical chemistry market, by others
FIG. 183 Decentralized clinical chemistry market, by rural health clinic
FIG. 184 Decentralized clinical chemistry market, by federally qualified health clinic
FIG. 185 Feces point-of-care (POC) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 186 Feces market, by hospital
FIG. 187 Feces market, by laboratories
FIG. 188 Feces market, by home care
FIG. 189 Feces market, by clinic
FIG. 190 Feces market, by physician office
FIG. 191 Feces market, by pharmacy & retail clinics
FIG. 192 Feces market, by non - practice clinics
FIG. 193 Feces market, by urgent care clinics
FIG. 194 Feces market, by others
FIG. 195 Feces market, by rural health clinic
FIG. 196 Feces market, by federally qualified health clinic
FIG. 197 Feces market, by colorectal cancer
FIG. 198 Feces market, by GI disorders
FIG. 199 Feces market, by others
FIG. 200 Lipid testing market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 201 Lipid testing market, by hospital
FIG. 202 Lipid testing market, by laboratories
FIG. 203 Lipid testing market, by home care
FIG. 204 Lipid testing market, by clinic
FIG. 205 Lipid testing market, by physician office
FIG. 206 Lipid testing market, by pharmacy & retail clinics
FIG. 207 Lipid testing market, by non - practice clinics
FIG. 208 Lipid testing market, by urgent care clinics
FIG. 209 Lipid testing market, by others
FIG. 210 Lipid testing market, by rural health clinic
FIG. 211 Lipid testing market, by federally qualified health clinic
FIG. 212 Lipid testing market, by hyperlipidemia
FIG. 213 Lipid testing market, by cardiovascular diseases
FIG. 214 Lipid testing market, by others
FIG. 215 Cancer marker market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 216 Cancer marker market, by hospital
FIG. 217 Cancer marker market, by laboratories
FIG. 218 Cancer marker market, by home care
FIG. 219 Cancer marker market, by clinic
FIG. 220 Cancer marker market, by physician office
FIG. 221 Cancer marker market, by pharmacy & retail clinics
FIG. 222 Cancer marker market, by non - practice clinics
FIG. 223 Cancer marker market, by urgent care clinics
FIG. 224 Cancer marker market, by others
FIG. 225 Cancer marker market, by rural health clinic
FIG. 226 Cancer marker market, by federally qualified health clinic
FIG. 227 Cancer marker market, by breast cancer
FIG. 228 Cancer marker market, by prostate cancer
FIG. 229 Cancer marker market, by colorectal cancer
FIG. 230 Cancer marker market, by kidney cancer
FIG. 231 Cancer marker market, by lung cancer
FIG. 232 Cancer marker market, by bladder cancer
FIG. 233 Cancer marker market, by other
FIG. 234 Cancer marker market, by marker
FIG. 235 Cancer marker
FIG. 236 Blood gas/electrolytes market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 237 Blood gas/electrolytes market, by hospital
FIG. 238 Blood gas/electrolytes market, by laboratories
FIG. 239 Blood gas/electrolytes market, by home care
FIG. 240 Blood gas/electrolytes market, by clinic
FIG. 241 Blood gas/electrolytes market, by physician office
FIG. 242 Blood gas/electrolytes market, by pharmacy & retail clinics
FIG. 243 Blood gas/electrolytes market, by non - practice clinics
FIG. 244 Blood gas/electrolytes market, by urgent care clinics
FIG. 245 Blood gas/electrolytes market, by others
FIG. 246 Blood gas/electrolytes market, by rural health clinic
FIG. 247 Blood gas/electrolytes market, by federally qualified health clinic
FIG. 248 Ambulatory chemistry market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 249 Ambulatory Chemistry market, by hospital
FIG. 250 Ambulatory Chemistry market, by laboratories
FIG. 251 Ambulatory Chemistry market, by home care
FIG. 252 Ambulatory Chemistry market, by clinic
FIG. 253 Ambulatory Chemistry market, by physician office
FIG. 254 Ambulatory Chemistry market, by pharmacy & retail clinics
FIG. 255 Ambulatory Chemistry market, by non - practice clinics
FIG. 256 Ambulatory Chemistry market, by urgent care clinics
FIG. 257 Ambulatory Chemistry market, by others
FIG. 258 Ambulatory Chemistry market, by rural health clinic
FIG. 259 Ambulatory Chemistry market, by federally qualified health clinic
FIG. 260 Drug abuse testing market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 261 Drug of abuse (DOA) testing market, by hospital
FIG. 262 Drug of abuse (DOA) testing market, by laboratories
FIG. 263 Drug of abuse (DOA) testing market, by home care
FIG. 264 Drug of abuse (DOA) testing market, by clinic
FIG. 265 Drug of abuse (DOA) testing market, by physician office
FIG. 266 Drug of abuse (DOA) testing market, by pharmacy & retail clinics
FIG. 267 Drug of abuse (DOA) testing market, by non - practice clinics
FIG. 268 Drug of abuse (DOA) testing market, by urgent care clinics
FIG. 269 Drug of abuse (DOA) testing market, by others
FIG. 270 Drug of abuse (DOA) testing market, by rural health clinic
FIG. 271 Drug of abuse (DOA) testing market, by federally qualified health clinic
FIG. 272 Urinalysis market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 273 Urinalysis/Nephrology market, by hospital
FIG. 274 Urinalysis/Nephrology market, by laboratories
FIG. 275 Urinalysis/Nephrology market, by home care
FIG. 276 Urinalysis/Nephrology market, by clinic
FIG. 277 Urinalysis/Nephrology market, by physician office
FIG. 278 Urinalysis/Nephrology market, by pharmacy & retail clinics
FIG. 279 Urinalysis/Nephrology market, by non - practice clinics
FIG. 280 Urinalysis/Nephrology market, by urgent care clinics
FIG. 281 Urinalysis/Nephrology market, by others
FIG. 282 Urinalysis/Nephrology market, by rural health clinic
FIG. 283 Urinalysis/Nephrology market, by federally qualified health clinic
FIG. 284 Urinalysis/Nephrology market, by UTI
FIG. 285 Urinalysis/Nephrology market, by kidney disease
FIG. 286 Urinalysis/Nephrology market, by diabetes
FIG. 287 Urinalysis/Nephrology market, by others
FIG. 288 North America point-of-care (POC) diagnostics & testing market: End - use outlook and key takeaways
FIG. 289 North America point-of-care (POC) diagnostics & testing market: End - use movement analysis
FIG. 290 Clinics market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 291 Pharmacy & Retail Clinics market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 292 Physician Office market estimates and forecast, 2018 - 2030 (USD Million))
FIG. 293 Urgent Care Clinics market estimates and forecast, 2018 - 2030 (USD Million))
FIG. 294 Non - practice Clinics market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 295 Others market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 296 Rural Health Clinic market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 297 Federally Qualified Health Clinic market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 298 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 299 Home Care market estimates and forecast,2018 - 2030 (USD Million)
FIG. 300 Self - testing Market for home,2018 - 2030 (USD Million)
FIG. 301 Self - collection Market for self - collection, 2018 - 2030 (USD Million)
FIG. 302 Laboratories Market for laboratory,2018 - 2030 (USD Million)
FIG. 303 North America point-of-care (POC) diagnostics & testing market: Type outlook and key takeaways
FIG. 304 North America point-of-care (POC) diagnostics & testing market: Type movement analysis
FIG. 305 LDT market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 306 Other POC market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 307 Regional marketplace: Key takeaways
FIG. 308 North America: SWOT analysis
FIG. 309 North America POC market estimates and forecasts, 2018 - 2030 (USD Million)
FIG. 310 Key country dynamics
FIG. 311 R&D Investments in medical and health, 2020
FIG. 312 U.S. POC market estimates and forecasts, 2018 - 2030 (USD Million)
FIG. 313 Key country dynamics
FIG. 314 Major therapeutic classes share, 2020 (%)
FIG. 315 Canada POC market estimates and forecasts, 2018 - 2030 (USD Million)
FIG. 316 Recent developments & impact analysis, by key market participants
FIG. 317 Marketing channels
FIG. 318 Market leaders, emerging companies, and key innovators
FIG. 319 Key customers
FIG. 320 Competitive landscape of North America POC diagnostics market for glucose monitoring - Major market participants
FIG. 321 Competitive landscape of North America POC diagnostics market for cardiac markers - Major market participants
FIG. 322 Competitive landscape of North America POC diagnostics market for hematology - Major market participants
FIG. 323 Competitive landscape of North America POC diagnostics market for fertility testing - Major market participants
FIG. 324 Competitive landscape of North America POC diagnostics market for infectious disease testing - Major market participants
FIG. 325 Competitive landscape of North America POC diagnostics market for decentralized clinical chemistry - Major market participants
FIG. 326 Competitive landscape of North America POC diagnostics market for oncology markers - Major market participants
FIG. 327 Competitive landscape of North America POC diagnostics market for blood gas testing - Major market participants
FIG. 328 Competitive landscape of North America POC diagnostics market for ambulatory chemistry - Major market participants
FIG. 329 Competitive landscape of North America POC diagnostics market for drugs of abuse testing - Major market participants
FIG. 330 Competitive landscape of North America POC diagnostics market for urinalysis - Major market participants
FIG. 331 Competitive dashboard analysis for public players
FIG. 332 Market participant categorization
FIG. 333 North America POC market share analysis, 2022
FIG. 334 Strategic framework
Companies Mentioned
- F. Hoffmann-La Roche AG
- QIAGEN
- Danaher Corporation
- BD
- bioMérieux SA
- Abbott
- Siemens Healthineers A.G.
- Zoetis, Inc.
- Instrumentation Laboratory
- Nova Biomedical
- Trividia Health, Inc.
- Quidel Corporation
- Trinity Biotech
- Sekisui Diagnostics
- OraSure Technologies, Inc.
- NIPRO
- Spectral Medical, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | January 2023 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 19.01 Billion |
| Forecasted Market Value ( USD | $ 28.46 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | North America |
| No. of Companies Mentioned | 17 |
